International Brand Name:
In treatment of:
Control of Ventricular and supraventricular arrhythmaias
Bradycardia ,Worsens heart failure ,Transient asystole, Constipation ,Hypotension,Palpitation, Flushing, Nausea, Edema, A-V block, Headache, Dizziness, Vasodilatation, Rashes, Nervousness, Vertigo, Paraesthesia, Abnormal liver functioning
Heart failure , 2nd and 3rd degree Heart block , Sick sinus syndrome, Hypersensitivity to the drug, Hypotension, Cardiogenic shock, Bradycardia, In digitalis toxicity, Wolff Parkinson white, syndrome.(atrial fibrillation with pre excitation), Tachyarrhythmias where QRS complex is wide unless a supraventricular origin is established
Bradycardia, Hypotension, Hypertrophic cardiomyopathy, Conduction disturbance, Impaired left, ventricular function, Congestive heart failure, First degree heart block, Hepatic impairment, Renal impairment, 10.Use cautiously along with other antihypertensive drugs,11.Use with caution along with digitalis and other antiarrhythmic drugs, 12.Slowly withdraw the drug with caution, 13.In thrombocytopenia and defective platelet function.
Histamine H2 antagonists: May enhance bioavailability.B-Blockers: Though advantageous in some, concomitant use results in increased adverse effects like bradycardia and conduction disturbances.Digitalis Glycosides: Increased serum digoxin levels.Magnesium Sulfate: With parenteral magnesium sulfate neuromuscular blockade and hypotension may occur.Theophyllines: Efficacy of theophylline increased.Quinidine: Hypotension, bradycardia, ventricular tachycardia, AV block and pulmonary oedema may occur.Fentanyl: Severe hypotension or increased fluid requirements.Barbiturates: Bioavailability of verapamil may be decreased.Rifampicin: Loss of efficacy of oral verapamil.Vitamin D: Efficacy of verapamil may be reduced.Carbamazepine: Serum level of carbamazepine may be increased.Cyclosporine: Increased cryclosporine levels with possible toxity. However,verapamil may be nephroprotective if given before cyclosporine.Lithium: Altered response. Non-depolarising muscle relaxants: Muscle relaxant effects may be increased, respiratory depression may be prolonged. Prazosin: May increase sensitivity to prazosin induced postural hypotension.
Oral: 120 to 320mg/day in 3 to 4 divided doses. Maximum dose: 480mg/day I.V.: Starts with 5mg. Repeat the therapy with same dose after 5 to 10minutes depending up on the patient`s response. On recurrence infuse 5 to 10mg/hour gradually up to 100mg if required depending up on the patient`s response Children (below 6years): Oral: 80 to 120mg in 2 to 3 divided doses 6 to 12 years: 80 to 320mg in 2 to 3 divided doses Maximum dose: 360mg/day Parenteral: Up to 1.5mg/kg/day and Starts with following doses 1 to 5 years: 2 to 3mg 6 to 14 years: 2.5 to 5mg Paroxysmal supraventricular tachycardia: 5mg I.V. over 2 to 3 minutes. Prevents recurrence with 60 to 120mg orally 8th hourly. Gradually increases the dose if required based on patient`s response. Atrial fibrillation and atrial flutter: 40 to 80mg 8th hourly orally. Gradually increases the dose if required based on patient`s response up to 320mg. Angina: 80 to 120mg 8th hourly. Gradually increases the dose if required based on patient`s response. Hypertension: 80mg 8th hourly. Gradually increases the dose if required based on patient`s response.